We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism.

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...